Expertise in
18
conditions

Dr. Sonali S. Chaudhury

Hematology | Oncology
Ann & Robert H. Lurie Children's Hospital Of Chicago
225 E Chicago Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
24 Years of Experience
Expertise in
18
conditions
Ann & Robert H. Lurie Children's Hospital Of Chicago
225 E Chicago Ave, 
Chicago, IL 

Overview

Sonali Chaudhury is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. She has been practicing medicine for over 24 years.

Dr. Chaudhury is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Sickle Cell Disease, Hemoglobinopathy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
225 E Chicago Ave, Chicago, IL 60611

Additional Areas of Focus

Dr. Chaudhury has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Enrollment Status: Recruiting
Publish Date: March 25, 2026
Intervention Type: Drug
Study Drugs: Stratum 1, Strata 2, 3, or 4, GVHD Regimen
Study Phase: Phase 1/Phase 2
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care
Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care
Enrollment Status: Completed
Publish Date: February 11, 2025
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial
Enrollment Status: Completed
Publish Date: June 13, 2024
Intervention Type: Drug, Procedure
Study Drugs: Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Sirolimus, Mycophenolate Mofetil
Study Phase: Phase 1
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
Enrollment Status: Unknown
Publish Date: December 05, 2023
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
A Phase II, Open Label, Multi-center Trial to Determine the Efficacy and Safety of Tisagenlecleucel Re-infusion in Pediatric and Adolescent Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B Cell Aplasia
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
View 8 Less Clinical Trials

79 Total Publications

Plasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults.
Plasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults.
Journal: Microbiology spectrum
Published: July 14, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Expertise in
26
conditions
Dr. Sonali M. Smith
Hematology | Oncology
Referral may be required

UChicago Medicine River East

355 E. Grand Ave., 
Chicago, IL 
 (0.4 miles away)
888-824-0200
Languages Spoken:
English, Greek, Gujarati , Hindi, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sonali Smith is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Smith is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Smith is board certified in Medical Oncology and Practicing Since2001. Dr. Smith is currently accepting new patients.

Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.4 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Gordon is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gordon is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Gordon is currently accepting new patients.

Expertise in
25
conditions
Dr. Reem M. Karmali
Hematology | Oncology
Expertise in
25
conditions
Dr. Reem M. Karmali
Hematology | Oncology
Referral may be required
Before you request
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (0.4 miles away)
866-587-4322
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Reem Karmali is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Karmali is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Karmali is board certified in American Board Of Internal Medicine - Hematology (Certified). Dr. Karmali is currently accepting new patients.

Frequently Asked Questions about Dr. Sonali S. Chaudhury

How do I make an appointment with Dr. Sonali S. Chaudhury?

You can book an appointment with Dr. Sonali S. Chaudhury by calling their office at 312-227-4090. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sonali S. Chaudhury a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sonali S. Chaudhury is classified as an Distinguished expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sonali S. Chaudhury specialize in?

While Dr. Sonali S. Chaudhury is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sonali S. Chaudhury participate in research or clinical trials?

Yes. Dr. Sonali S. Chaudhury has published 79 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Sonali S. Chaudhury's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sonali S. Chaudhury accept my insurance?

Dr. Sonali S. Chaudhury accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 312-227-4090 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaudhury's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile